SCHEMBL19069999

SCHEMBL19069999

C/C=C\C1=C(C)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11564976 1.00
SCHEMBL18545393 0.95 SLC6A3 (0.39)
SCHEMBL2687387 0.95 SLC6A3 (0.39)
SCHEMBL22369528 0.83
SCHEMBL21393010 0.83 APP (0.33)
SCHEMBL21393127 0.83 SLC6A3 (0.39)
SCHEMBL11853474 0.78
SCHEMBL793251 0.76
SCHEMBL3946329 0.75 APP (0.30)
SCHEMBL19426999 0.75 SLC6A3 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228688-A1 POLYMER AND COMPOSITION THEREOF SHANGHAI SENHUI MEDICINE CO., LTD. (CN) 2024-07-11 US disclosed
US-20240208981-A1 NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-27 US disclosed
US-20240024498-A1 PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2024-01-25 US disclosed
US-20230295094-A1 NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) 2023-09-21 US disclosed
US-20230241242-A1 PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2023-08-03 US disclosed
US-11697646-B2 Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2023-07-11 US disclosed
US-11666623-B2 Tetramaleimide linkers and use thereof NEWBIO THERAPEUTICS, INC. (CN) 2023-06-06 US disclosed
EP-3852747-B1 CYCLOHEPTYL ACIDS AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2023-05-31 EP disclosed
US-11661437-B2 Steroid derivative regulators, method for preparing the same, and uses thereof JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-05-30 US disclosed
US-20230144203-A1 DRUG CONJUGATE OF ERIBULIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2023-05-11 US disclosed
US-20190152959-A1 PROCESSES FOR PREPARING PYRIDINE CARBOXAMIDE DERIVATIVES JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2019-05-23 US disclosed
US-20190127362-A1 SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2019-05-02 US disclosed
US-20190039057-A1 METAL CATALYST, METHOD OF C-N COUPLING USING THE SAME AND APPLICATIONS OF THE SAME BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS 2019-02-07 US disclosed
US-10010631-B2 Ligands for imaging cardiac innervation LANTHEUS MEDICAL IMAGING, INC. (US) 2018-07-03 US disclosed
US-20180177890-A1 LIGAND-CYTOTOXIC DRUG CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2018-06-28 US disclosed
US-20180170943-A1 PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2018-06-21 US disclosed
US-20180118750-A1 IMIDAZO ISOINDOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2018-05-03 US disclosed
US-9895355-B2 Methods of treating androgen receptor-mediated disorders with imidazoline derivatives Shanghai Hengru Pharmaceutical Co., Ltd. (CN) 2018-02-20 US disclosed
US-20170342059-A1 PYRIDINECARBOXAMIDE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USES THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2017-11-30 US disclosed
EP-2841437-B1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2017-07-05 EP disclosed